Last reviewed · How we verify
AGA2115
AGA2115 is a small molecule drug that targets the PI3K/AKT/mTOR pathway.
AGA2115 is a small molecule drug that targets the PI3K/AKT/mTOR pathway. Used for Advanced solid tumors.
At a glance
| Generic name | AGA2115 |
|---|---|
| Sponsor | Angitia Incorporated Limited |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AGA2115 works by inhibiting the PI3K/AKT/mTOR pathway, which is involved in cell proliferation and survival. This inhibition leads to anti-tumor effects. The exact mechanism of action is not fully understood.
Approved indications
- Advanced solid tumors
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
- Osteogenesis Imperfecta Trial of AGA2115 for ADUlts With COL1A1 and/or COL1A2 GeNetic Variations (IDUN) (PHASE2)
- A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGA2115 CI brief — competitive landscape report
- AGA2115 updates RSS · CI watch RSS
- Angitia Incorporated Limited portfolio CI